- Company is restructuring with the goal of extending cash runway to mid-2022
- Workforce to be reduced by 54%
- Company to focus on completing Phase 3 dermatomyositis study and advancing preclinical pipeline into the clinic
Norwood, MA, Oct. 08, 2020 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS), today announced a restructuring of its workforce designed to reallocate capital to certain clinical and preclinical programs.
Corbus will allocate resources towards its lenabasum clinical developmen…